Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Page 1
Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E. Kourakis S, et al. Pharmaceuticals (Basel). 2020 Oct 13;13(10):306. doi: 10.3390/ph13100306. Pharmaceuticals (Basel). 2020. PMID: 33066228 Free PMC article. Review.
Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing-Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune-mediated aetiology, driven by severe inflammation and oxidative …
Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing-Rem …
Defining Pre-Clinical Psoriatic Arthritis in an Integrated Dermato-Rheumatology Environment.
Savage L, Tinazzi I, Zabotti A, Laws PM, Wittmann M, McGonagle D. Savage L, et al. J Clin Med. 2020 Oct 12;9(10):3262. doi: 10.3390/jcm9103262. J Clin Med. 2020. PMID: 33053820 Free PMC article. Review.
In excess of three quarters of patients with psoriatic arthritis (PsA) have preceding psoriasis (PsO), which offers a clinical biomarker for the recognition of early PsA. Numerous surveys have shown a remarkably high frequency of clinically occult musculoskeletal symptoms …
In excess of three quarters of patients with psoriatic arthritis (PsA) have preceding psoriasis (PsO), which offers a clinical biomar …
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis.
Näslund-Koch C, Zachariae C, Skov L. Näslund-Koch C, et al. Ther Clin Risk Manag. 2020 Sep 24;16:903-916. doi: 10.2147/TCRM.S227880. eCollection 2020. Ther Clin Risk Manag. 2020. PMID: 33061395 Free PMC article. Review.
Psoriasis is a common immune-mediated chronic inflammatory disease, and observations have pointed toward the IL-23/Th17 cell axis as having a key role in the pathogenesis of psoriasis. ...However, to determine its position in the treatment algorithm of psoriasis …
Psoriasis is a common immune-mediated chronic inflammatory disease, and observations have pointed toward the IL-23/Th17 cell axis as …
Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6.
Wang H, Yang G, Zhang Q, Liang X, Liu Y, Gao M, Guo Y, Chen L. Wang H, et al. Aging (Albany NY). 2020 Oct 14;12(19):19012-19021. doi: 10.18632/aging.103665. Epub 2020 Oct 14. Aging (Albany NY). 2020. PMID: 33052879 Free PMC article.
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor used in the treatment of psoriasis and several other inflammatory diseases. Interest has been expressed in seeking out therapies that address both psoriasis and atherosclerosis. ...
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor used in the treatment of psoriasis and several other inflammatory diseases. Inte …
Long-Term and Clinically Relevant Full-Thickness Human Skin Equivalent for Psoriasis.
Singh S, Marquardt Y, Rimal R, Nishiguchi A, Huth S, Akashi M, Moeller M, Baron JM. Singh S, et al. ACS Appl Bio Mater. 2020 Oct 19;3(10):6639-6647. doi: 10.1021/acsabm.0c00202. Epub 2020 Sep 17. ACS Appl Bio Mater. 2020. PMID: 35019390 Free PMC article.
Psoriasis is an incurable, immune-mediated inflammatory disease characterized by the hyperproliferation and abnormal differentiation of keratinocytes. ...
Psoriasis is an incurable, immune-mediated inflammatory disease characterized by the hyperproliferation and abnormal differentiation …
Incentives for Danish healthcare management based on a pilot outcome-based, patient-centric management model in psoriasis and psoriatic arthritis: the non-interventional IMPROVE study.
Thomsen SF, Skov L, Kristensen LE, Hedegaard MS, Kjellberg J, Jørgensen TS, Brenøe S, Dodge R. Thomsen SF, et al. Arch Public Health. 2020 Oct 12;78:95. doi: 10.1186/s13690-020-00479-y. eCollection 2020. Arch Public Health. 2020. PMID: 33062265 Free PMC article.
BACKGROUND: Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic diseases that affect patients' quality of life. ...
BACKGROUND: Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic diseases that affect patients' quality of life. ...
Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey.
Orbai AM, Birt JA, Holdsworth EA, Booth N, Malatestinic WN, Sprabery AT, Reginato AM. Orbai AM, et al. Rheumatol Ther. 2020 Dec;7(4):937-948. doi: 10.1007/s40744-020-00242-3. Epub 2020 Oct 14. Rheumatol Ther. 2020. PMID: 33052584 Free PMC article.
Those with enthesitis had worse overall disease severity compared to those without enthesitis (12.2% vs 2.2% severe) and had more extraarticular manifestations, including nail psoriasis, dactylitis, and sacroiliitis. Enthesitis was associated with more pain, worse quality …
Those with enthesitis had worse overall disease severity compared to those without enthesitis (12.2% vs 2.2% severe) and had more extraartic …